Managers / Q4 2024 · view latest →
venBio Partners LLC
CIK 0001776382 · 1700 OWENS STREET, SUITE 595, SAN FRANCISCO, CA, 94158 · 415-522-0100
Summary
Venbio Partners LLC reported $171M in U.S.-listed holdings across 7 positions for Q4 2024.
The portfolio is heavily concentrated: Pharvaris N V alone accounts for 48.2% of reported value.
Compared with Q3 2024, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 57.8% · $99M
- Common Stock · 42.2% · $72M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| LYELL IMMUNOPHARMA INC | NEW | +7.10M | 7.10M | +$5M | $5M |
| HRMYHARMONY BIOSCIENCES HLDGS IN | TRIMMED | −75.4K | 539.2K | −$6M | $19M |
| ALMSALUMIS INC | HELD | −38.6K | 2.79M | −$8M | $22M |
| ACELYRIN INC | HELD | −46.1K | 3.81M | −$7M | $12M |
| ARTVARTIVA BIOTHERAPEUTICS INC | HELD | +0 | 1.52M | −$8M | $15M |
| PHARVARIS N V | HELD | +0 | 4.29M | +$3M | $82M |
| ALXOALX ONCOLOGY HLDGS INC | HELD | +0 | 9.70M | −$1M | $16M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | PHARVARIS N V | COM | 48.17% | $82M | 4.29M |
| 2 | ALMSALUMIS INChistory → | COM | 12.83% | $22M | 2.79M |
| 3 | HRMYHARMONY BIOSCIENCES HLDGS INhistory → | COM | 10.87% | $19M | 539.2K |
| 4 | ALXOALX ONCOLOGY HLDGS INChistory → | COM | 9.49% | $16M | 9.70M |
| 5 | ARTVARTIVA BIOTHERAPEUTICS INChistory → | COM | 8.98% | $15M | 1.52M |
| 6 | ACELYRIN INC | COM | 7.00% | $12M | 3.81M |
| 7 | LYELL IMMUNOPHARMA INC | COM | 2.66% | $5M | 7.10M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $281M | 6 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $216M | 6 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $176M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $115M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $124M | 7 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $171M | 7 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $194M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $232M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $282M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $667M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $353M | 8 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $276M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $323M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $432M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $351M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $451M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $555M | 9 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.0B | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $847M | 10 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.1B | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.1B | 7 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $658M | 8 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $120M | 4 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $38M | 3 | May 26, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $233M | 6 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $211M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $212M | 6 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $116M | 4 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.